​

VYNE Therapeutics (VYNE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

VYNE Stock Forecast

VYNE Therapeutics (VYNE) stock forecast, based on 2 Wall Street analysts, predicts a 12-month average price target of $5.75, with a high of $5.75 and a low of $5.75. This represents a 130.00% increase from the last price of $2.50.

$1 $2 $3 $4 $5 $6 High: $5.75 Avg: $5.75 Low: $5.75 Last Closed Price: $2.5

VYNE Stock Rating

VYNE Therapeutics stock's rating consensus is Buy, based on 2 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 2 0 2 Strong Sell Sell Hold Buy Strong Buy

VYNE Forecast vs Benchmarks

TypeNameUpside
StockVYNE Therapeutics130.00%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$5.75
Last Closing Price$2.50$2.50$2.50
Upside/Downside--130.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2513---4
Dec, 2413---4
Nov, 2413---4
Oct, 2413---4
Sep, 2413---4
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 14, 2024Joseph PantginisH.C. Wainwright$5.75$2.11172.51%130.00%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Sep 13, 2024H.C. WainwrightBuyBuyhold
Aug 15, 2024Cowen & Co.BuyBuyhold
Aug 15, 2024H.C. WainwrightBuyBuyhold
Jun 14, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-150 $-120 $-90 $-60 $-30 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-141.90$-25.65$-10.65$-2.77-----
Avg Forecast$-55.04$-24.03$-8.52$-7.66$-0.96$-1.13$-1.16$-1.00$-1.65
High Forecast$-58.16$-25.39$-9.53$-7.66$-0.97$-1.13$-1.38$-1.00$-1.65
Low Forecast$-51.93$-22.67$-7.51$-7.66$-0.95$-1.13$-0.94$-1.00$-1.65
Surprise %157.81%6.74%25.00%-63.84%-----

Revenue Forecast

$0 $5M $10M $15M $20M $25M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$20.99M$14.76M$477.00K$424.00K-----
Avg Forecast$21.43M$17.26M$366.67K$500.00K$533.33K$250.00K$300.00K$10.25M$13.60M
High Forecast$20.50M$16.51M$333.33K$500.00K$533.33K$250.00K$300.00K$10.25M$13.60M
Low Forecast$22.36M$18.01M$400.00K$500.00K$533.33K$250.00K$300.00K$10.25M$13.60M
Surprise %-2.03%-14.51%30.09%-15.20%-----

Net Income Forecast

$-600M $-480M $-360M $-240M $-120M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-255.57M$-73.33M$-33.95M$-28.45M-----
Avg Forecast$-565.47M$-74.41M$-78.61M$-28.02M$-9.86M$-11.61M$-11.92M$-10.27M$-16.95M
High Forecast$-597.43M$-89.29M$-94.34M$-33.63M$-9.96M$-11.61M$-14.18M$-10.27M$-16.95M
Low Forecast$-533.51M$-59.53M$-62.89M$-22.42M$-9.76M$-11.61M$-9.66M$-10.27M$-16.95M
Surprise %-54.80%-1.45%-56.82%1.54%-----

VYNE Forecast FAQ

Is VYNE Therapeutics stock a buy?

VYNE Therapeutics stock has a consensus rating of Buy, based on 2 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that VYNE Therapeutics is a favorable investment for most analysts.

What is VYNE Therapeutics's price target?

VYNE Therapeutics's price target, set by 2 Wall Street analysts, averages $5.75 over the next 12 months. The price target range spans from $5.75 at the low end to $5.75 at the high end, suggesting a potential 130.00% change from the previous close price of $2.5.

How does VYNE Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

VYNE Therapeutics stock forecast shows a 130.00% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for VYNE Therapeutics over the past three months?

  • January 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is VYNE Therapeutics’s EPS forecast?

VYNE Therapeutics's average annual EPS forecast for its fiscal year ending in December is -0.96 for 2024, a -65.34% decrease from the reported $-2.77 in 2023. The prediction for 2025 is $-1.13, $-1.16 for 2026, $-1 for 2027, and $-1.65 for 2028.

What is VYNE Therapeutics’s revenue forecast?

VYNE Therapeutics's average annual revenue forecast for its fiscal year ending in December is $533.33K for 2024, a 25.79% increase from the reported $424K in 2023. The forecast for 2025 is $250K, $300K for 2026, $10.25M for 2027, and $13.6M for 2028.

What is VYNE Therapeutics’s net income forecast?

For its fiscal year ending in December, VYNE Therapeutics's average annual net income forecast is $-9.862M for 2024, reflecting a -65.34% decrease from the reported $-28.452M in 2023. The projection for 2025 is $-11.608M, $-11.917M for 2026, $-10.273M for 2027, and $-16.95M for 2028.